Read & Download your Issue of Monday – January 11 FNN News

UK to begin using Oxford Covid vaccine as PM strikes hopeful tone

• People in the UK will begin receiving the Oxford/AstraZeneca vaccine
• In England the first doses would be administered in a small number of hospitals for surveillance purposes, said the NHS.
• The NHS has 530,000 doses of the Oxford/AstraZeneca vaccine that have been approved and are ready for use.
• The first priority is to immunise care home residents.

Source: The Guardian

Covid-19: Antibodies protect against reinfection for at least six months, study finds

• The presence of SARS-CoV-2 antibodies confers subsequent immunity in most people for at least six months, a study of healthcare workers in Oxford, UK, has found.
• Reports of SARS-CoV-2 reinfection had been rare, suggesting that initial infection confers protective immunity, and that small scale studies suggest that this immunity is antibody mediated rather than cell mediated.
• The results showed that positive antibody test results were associated with a lower rate of subsequent PCR positivity, suggesting a protective effect of the immune response to the original infection.

Source: BMJ

Effect of remote management on comprehensive management of diabetes mellitus during the COVID-19 epidemic

• During the COVID-19 epidemic, diabetes treatment is facing new challenges and the traditional treatment mode is limited.
• Remote management can manage people with diabetes outside the hospital during the COVID-19 epidemic.
• Remote management can improve TIR without increasing the risk of hypoglycemia and improve self-management ability and compliance.
• They conducted a randomized controlled study to confirm the effectiveness of remote management using the mobile phone WeChat app on comprehensive management of diabetes mellitus during the COVID-19 epidemic.

Source: ScienceDirect

Rare SARS-CoV-2 antibody development in cancer patients

• SARS-CoV-2 antibody development and immunity will be crucial for the further course of the pandemic.
• Until now, it has been assumed that patients who are infected with SARS-CoV-2 will develop antibodies as has been the case with other coronaviruses.
• In the present study, they analyzed the development of antibodies in 77 patients with an oncologic diagnosis 26 days after positive RT-qPCR testing for SARS-CoV2.
• Surprisingly, antibody development was detected in only 6 of 77 individuals with a confirmed history of COVID-19.

Source: ScienceDirect

Low vitamin D status is associated with coronavirus disease 2019 outcomes: A systematic review and meta-analysis

• Observational studies suggest that the risk and clinical prognosis of coronavirus disease 2019 (COVID-19) are related to low vitamin D status; however, the data are inconsistent.
• They conducted a systematic review and meta-analysis to assess the association between low vitamin D status and COVID-19.
• This systematic review and meta-analysis indicated that low vitamin D status may be associated with an increased risk of COVID-19 infection.
• Further studies are needed to evaluate the impact of vitamin D supplementation on the clinical severity and prognosis in patients with COVID-19.

Source: ScienceDirect

The impact of COVID-19 on private and public primary care physicians: A cross-sectional study

• Primary care physicians (PCP) are at a high risk of contracting COVID-19 as they manage patients with fever or respiratory symptoms, but it is intuitive that private and public practice PCPs may face different challenges during this pandemic.
• This study compared work- and non-work-related concerns, COVID-19’s impact on personal and professional lives, and perceived pandemic preparedness between private and public PCPs in Singapore.

Source: ScienceDirect

• Read more from FADIC Blog, with many articles with evidence based articles.
• Learn More Through FADIC® – Online Programs & Mini-Courses.
• Listen Now to FADIC Podcast focusing on varieties of pharmacist perspectives in specialties.
• Read More Now about FADIC Pharmacy Events to get more Experience.

Course Copyrights:

All Courses is meant for SINGLE user use only.
If more than one person acceced this course, they will be BLOCKED Forever.

Why FADIC 2021 Antimicrobial Resistance E-News (FNN) Daily Emails?

• It helps to keep up with the literature!
• Provide you with the Updated with the latest in your clinical practice. Wherever you are, and Whenever you need!
• Help you to share in the advance in clinical career. In addition to adding an impressive image to the pharmacists all-around!

Subscribe to FADIC 2020 Antimicrobial Resistance E-News (FNN), for daily publication of Daily News

Read & Download FNN Issue 8 of April 2020 FNN News